Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Taiwan / NCT06494696
Recruiting Observational

68Ga-PSMA PET/MRI in Conjunction With mpMRI for Evaluating Prospective Prostate Cancer Risk

NCT06494696 · tracked via the Priya Life Science Taiwan tracker
Sponsor
Chang Gung Memorial Hospital
Phase
Observational
Started
2024-07-01
Last updated
2024-07-10

Condition(s) studied

Prostate Cancer

Investigational drug(s) / intervention(s)

Ga-68 PSMA PET/MRI

Ga-68 PSMA PET/MRI: The participant will undergo a Ga-68 PSMA PET/MRI scan, and then be followed up for 2 years to see if prostate cancer is diagnosed.

Study summary

The goal of this observational study is to learn if Ga-68 PSMA PET/MRI can better diagnose prostate cancer than mpMRI in males between 40 to 85 years old who is naive to prostate biopsy and is suspicious for prostate cancer by elevated PSA or lower urinary tract symptoms. The main questions it aims to answer are:

1. Does PSMA PET/MRI have better PPV and NPV than mpMRI to diagnose prostate cancer?
2. Does lesion location concordance in PSMA PET and MRI effect diagnosis accuracy?

Participants will:

1. Undergo a Ga-68 PSMA PET/MRI scan and keep followed up for 2 years to check if prostate cancer is diagnosed after the scan.
2. Between the follow-up period, visit the clinic once every 6 months for checkups and blood tests.

Eligibility

Sex
MALE
Min age
40 Years
Max age
85 Years
Healthy volunteers
Accepted
Inclusion Criteria: 1. Patients who indicated MRI of pelvis due to clinical suspicion of prostate cancer based on elevated PSA (4\~20 ng/mL), abnormal digital rectal examination or lower urinary tract syndromes. 2. Males aged between 40 and 85 years with a life expectancy greater than two years. 3. Naïve to prostate biopsy in the past. 4. Assessment of daily physical status graded 0 to 2 based on the Eastern Cooperative Oncology Group (ECOG) criteria. 5. Willing to sign the informed consent. Exclusion Criteria: 1. Unable to tolerate the PET/MRI scan, such as those with claustrophobia, unable to lie still, consciousness unclear, vital sign unstable, or having MRI unsafe metallic implants or devices. 2. With renal impairment (glomerular filtration rate lower than 30 ml/min/1.73 m2), and allergy to medium contrast. 3. High risk to conduct examination after evaluations of PI 4. Patient had previous malignancy history

Primary outcome measure(s)

  • PPV of concordant PET/MRI lesion plus PI-RADS score 4~5 — 2 years after PSMA PET/MRI scan
    Comparing positive predictive values (PPV) of using concordant PET/MRI lesion plus PI-RADS score 4\~5 as positive test with PPV of using PI-RADS 4\~5 alone as positive test to predict diagnosing prostate cancer within 2 years.
  • NPV of using negative PET lesion plus PI-RADS score 1~3 — 2 years after PSMA PET/MRI scan
    Comparing negative predictive values (NPV) of using negative PET lesion plus PI-RADS score 1\~3 as negative test with NPV of using PI-RADS 1\~3 alone as negative test to predict diagnosing prostate cancer within 2 years.

Trial sites (1)

FacilityCityRegionStatus
Chang Gung Memorial Hospital ,Linkou Taoyuan City Taiwan Recruiting

More Chang Gung Memorial Hospital trials in Taiwan

Photon Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCC Recruiting
Fractional Exhaled Nitric Oxide and Exacerbations of COPD Starting soon
Predicting Clinical Efficacy of Immunotherapy Using Pre-treatment andContinuousMonitoring of PD-L1 TPS/CPS on CTCs, and Immunity Exhaustion Scores Recruiting
Dendritic Cell-immunotherapy for Advanced Hepatocellular Carcinoma Active, not recruiting
Dinutuximab-beta and Chemotherapy in Newly Diagnosed High-Risk Neuroblastoma Recruiting

Other trials for the same condition

A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study Active, not recruiting
Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy Recruiting
Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer Recruiting
Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC) Active, not recruiting
Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06494696 on ClinicalTrials.gov ↗ ← All trials in Taiwan